N,N-Dimethyl-5-(3-phenylpropyl)-1H-tetrazole-1-carboxamide | 1010096-67-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N-Dimethyl-5-(3-phenylpropyl)-1H-tetrazole-1-carboxamide
• 英文别名: N,N-dimethyl-5-(3-phenylpropyl)tetrazole-1-carboxamide
• CAS: 1010096-67-9
• 化学式: C₁₃H₁₇N₅O
• 分子量: 259.311
• InChiKey: WOOICPVINVVNOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  63.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-(3-phenylpropyl)-1H-tetrazole 、 二甲氨基甲酰氯 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 15.0h， 以38%的产率得到N,N-dimethyl-5-(3-phenylpropyl)-2Htetrazole-2-carboxamide
  参考文献：
  名称：

  Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: A critical revisitation

  摘要：

  We have synthesized a series of 18 1,5- and 2,5-disubstituted carbamoyl tetrazoles, including LY2183240 (1) and LY2318912 (7), two compounds previously described as potent inhibitors of the cellular uptake of the endocannabinoid anandamide, and their regioisomers 2 and 8. We confirm that compound 1 is a potent inhibitor of both the cellular uptake and, like the other new compounds synthesized here, the enzymatic hydrolysis of anandamide. With the exception of 9, 12, 15, and the 2,5-regioisomer of LY2183240 2, the other compounds,were all found to be weakly active or inactive on anandamide uptake. Several compounds also inhibited the enzymatic hydrolysis of the other main endocannabinoid, 2-arachidonoylglycerol, as well as its enzymatic release from sn-1-oleoyl-2-arachidonoyl-glycerol, at submicromolar concentrations. Four of the novel compounds, i.e. 3, 4, 17, and 18, inhibited anandamide hydrolysis potently (IC(50) = 2.1-5.4 nM) and selectively over all the other targets tested (IC(50) >= 10 mu M), thus representing new potentially useful tools for the inhibition of fatty acid amide hydrolase. (C) 2007 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2007.02.023

文献信息

• Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
  申请人：Pearson James Philip

  公开号：US20130150346A1

  公开（公告）日：2013-06-13

  The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors to treat aspects of Parkinson's disease (PD), restless legs syndrome (RLS) and periodic limb movement disorder (PLMD), the use of FAAH inhibitors for the manufacture of medicaments for use in the treatment of PD, RLS and PLMD, as well as pharmaceutically acceptable compositions comprising FAAH inhibitors for use in the treatment of PD, RLS and PLMD.
• Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
  申请人：Pearson James Philip

  公开号：US20130224151A1

  公开（公告）日：2013-08-29

  The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors alone or in combination for the treatment or prevention of abdominal, visceral or pelvic pain. Also described herein are pharmaceutical compositions comprising a FAAH inhibitor, alone or in combination with an additional therapeutic agent for the treatment of abdominal, visceral or pelvic pain.